SCHEMBL23999403

SCHEMBL23999403

Cc1cc(Nc2ccc3[nH]c(-c4ccc(Nc5cc(C)nc6ccc(C#N)cc56)cc4)nc3n2)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 2/20 0.43
▸ MAPKAPK2 P49137 2/20 0.42
▸ KDR P35968 4/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CSNK1A1 P48729 3/20 0.38
▸ CSNK1D P48730 3/20 0.38
▸ GSK3B P49841 3/20 0.38
▸ CSNK1G2 P78368 3/20 0.38
▸ PRMT5 O14744 1/20 0.37
▸ PKN1 Q16512 1/20 0.36
▸ PKN2 Q16513 1/20 0.36
▸ ABCG2 Q9UNQ0 1/20 0.36
▸ EHMT2 Q96KQ7 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ RAD52 P43351 1/20 0.36
▸ ROCK2 O75116 1/20 0.36
▸ GAK O14976 1/20 0.35
▸ RIPK2 O43353 1/20 0.35
▸ COQ8A Q8NI60 1/20 0.35
▸ NLK Q9UBE8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23999401 0.93 MAPKAPK2 (0.51) LRRK2MAPKAPK2KDRCSNK1A1CSNK1D
SCHEMBL23999407 0.92 LRRK2 (0.38) LRRK2MAPKAPK2KDRCSNK1A1CSNK1D
SCHEMBL23999409 0.90 LRRK2 (0.40) LRRK2MAPKAPK2L3MBTL1CSNK1A1CSNK1D
SCHEMBL23999400 0.85 MAPKAPK2 (0.43) LRRK2MAPKAPK2KDRPRMT5ROCK2
SCHEMBL30180523 0.84 MAPKAPK2 (0.49) LRRK2MAPKAPK2KDRCSNK1A1CSNK1D
SCHEMBL24004064 0.84 MAPKAPK2 (0.49) LRRK2MAPKAPK2KDRCSNK1A1CSNK1D
SCHEMBL23999612 0.83 DNMT1 (0.41) POLBRAD52
SCHEMBL23999399 0.82 MAPKAPK2 (0.42) LRRK2MAPKAPK2KDRCSNK1A1CSNK1D
SCHEMBL23999402 0.82 MAPKAPK2 (0.43) LRRK2MAPKAPK2KDRL3MBTL1CSNK1A1
SCHEMBL24010188 0.81 ABCG2 (0.41) LRRK2MAPKAPK2KDRGSK3BABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 — — US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 — — US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2021226519-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR LRRK2 500/4885MAPKAPK2 138/4885KDR 3271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback